Short- and Long-term Healthcare Resource Utilization in Parkinson’s Disease – 20 years of Follow Up in a Population-based Cohort
Objective: To assess Parkinson’s disease (PD) burden by means of healthcare resource utilization (HCRU) and clinical outcomes in Israeli PD patients during 20-year period ,2000…Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
Objective: To estimate the number of individuals living with PD globally in 2020. Background: Although previous studies have estimated PD prevalence in many countries, the…Clinical and demographic characteristics of patients with Functional Movement Disorders in Spain: a Consecutive Cohort Study
Objective: This study aims to describe the clinical and sociodemographic features of patients diagnosed with a functional movement disorder (FMD) at our specialised FMD clinic.…Analysing an extension type of Parkinson’s disease
Objective: We analyse an extension type of Parkinson’s disease. Background: At the International Congress of the Movement Disorder Society last year, we reviewed a patient…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…Evaluation of Cortical Excitability in Huntington’s Disease and Parkinson’s Disease
Objective: To evaluate the cortical excitability difference in Huntington's disease (HD) and Parkinson's disease (PD) using paired-pulse transcranial magnetic stimulation (TMS). Background: TMS is useful…Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism
Objective: To determine diagnostic accuracy of P/M, MRPI, and new indices termed P/M2.0 and MRPI2.0 (multiplying P/M and MRPI by third ventricle width/frontal horns width…Copper induced neurobehavioral features of Parkinson’s disease and oxidative stress and their abatement by Eugenol
Objective: The aim of this study was to evaluate impact of copper intoxication (10 mg/kg B.W) for 3 days on locomotor performance and oxidative status,…Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey
Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…A novel phasic and restricted basal ganglia thalamocortical subcircuitry model
Objective: To advance a novel basal ganglia thalamocortical (BGTC) model that accounts for GPi as a tonic-burst mode regulator of the thalamus and for restricted…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 149
- Next Page »